CVS Health (CVS) Stock Forecast & Price Target

$56.83 +1.06 (+1.90%)

(As of 11/20/2024 ET)

CVS Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
0

Hold
7

Buy
13

Based on 20 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 7 have given a hold rating, and 13 have given a buy rating for CVS.

Consensus Price Target

$72.28
27.18% Upside

According to the 20 analysts' twelve-month price targets for CVS Health, the average price target is $72.28. The highest price target for CVS is $94.00, while the lowest price target for CVS is $58.00. The average price target represents a forecasted upside of 27.18% from the current price of $56.83.

Get the Latest News and Ratings for CVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CVS Health and its competitors.

CVS Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)	11 Buy rating(s)
Hold	7 Hold rating(s)	8 Hold rating(s)	10 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$72.28	$75.26	$73.24	$92.59
Forecasted Upside	27.18% Upside	32.39% Upside	24.66% Upside	33.91% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CVS Health Stock vs. The Competition

Type	CVS Health	Retail/Wholesale Companies	S&P 500
Consensus Rating Score	2.65	2.51	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	27.18% Upside	30.48% Upside	9.81% Upside
News Sentiment Rating	Positive News See Recent CVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/20/2024	Truist Financial 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$76.00 ➝ $67.00	+18.06%
11/18/2024	Wells Fargo & Company 3 of 5 stars	S. Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$60.00 ➝ $66.00	+24.08%
11/15/2024	Royal Bank of Canada 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$68.00 ➝ $58.00	+8.33%
11/7/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$60.00 ➝ $62.00	+4.11%
11/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Mok Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$75.00 ➝ $71.00	+17.78%
10/24/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$73.00 ➝ $66.00	+16.24%
Get the Latest News and Ratings for CVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CVS Health and its competitors with MarketBeat's FREE daily newsletter.
10/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$62.00 ➝ $75.00	+14.26%
10/4/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Rhyee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$59.00 ➝ $85.00	+35.09%
10/1/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$62.00 ➝ $62.00	+0.27%
8/9/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$64.00 ➝ $63.00	+10.24%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$101.00 ➝ $86.00	+53.54%
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$61.00	+13.55%
5/8/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Graja Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$100.00 ➝ $80.00	+44.85%
5/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$95.00 ➝ $77.00	+41.73%
5/2/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$85.00 ➝ $74.00	+36.08%
5/1/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/1/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform	$87.00 ➝ $60.00	+5.60%
3/15/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$93.00 ➝ $94.00	+21.75%
12/22/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$94.00	+19.56%
11/2/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$110.00 ➝ $100.00	+43.55%
10/10/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$93.00 ➝ $80.00	+11.41%
9/12/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Peer Perform ➝ Outperform	$80.00	+16.36%
8/17/2023	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
8/4/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$90.00 ➝ $85.00	+14.34%
5/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$125.00 ➝ $96.00	+35.82%
2/9/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$130.00 ➝ $143.00	+60.75%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:52 AM ET.

Should I Buy CVS Health Stock? CVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, November 4, 2024. Please send any questions or comments about these CVS Health pros and cons to contact@marketbeat.com.

CVS Health
Bull Case

Here are some ways that investors could benefit from investing in CVS Health Co.:

CVS Health Co. has a dividend yield of 4.58%, providing investors with a steady income stream. A higher dividend yield can be attractive to income-seeking investors.
Recent stock performance shows CVS Health Co. trading at $64.59, indicating a potential for capital appreciation. A rising stock price can lead to capital gains for investors.
CVS Health Co. reported a return on equity of 12.72%, showcasing the company's ability to generate profit from shareholders' equity. A higher return on equity is generally favorable for investors.
Analysts expect CVS Health Co. to post 6.51 EPS for the current fiscal year, indicating potential earnings growth. Higher earnings per share can positively impact stock prices and investor returns.
CVS Health Co. operates through various segments, including Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness, diversifying its revenue streams and potentially reducing risk for investors.

CVS Health
Bear Case

Investors should be bearish about investing in CVS Health Co. for these reasons:

CVS Health Co. has a debt-to-equity ratio of 0.83, indicating a significant level of debt compared to equity. High debt levels can pose financial risks and impact the company's financial stability.
The company's stock price has experienced fluctuations, with a 52-week high of $83.25 and a 52-week low of $52.77. Volatility in stock prices can lead to uncertainty for investors.
CVS Health Co. has a beta of 0.54, suggesting lower volatility compared to the market. While lower volatility can be perceived as less risky, it may also limit potential returns for investors seeking higher-risk investments.
The company's revenue growth was modest at 2.6% compared to the same quarter last year. Slower revenue growth rates may indicate challenges in expanding the business and could impact future stock performance.
Despite a consensus rating of "Moderate Buy," there have been mixed analyst opinions on CVS Health Co., with some recommending a hold rating. Differing analyst views may lead to uncertainty among investors regarding the company's future prospects.

CVS Forecast - Frequently Asked Questions

: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $72.28, with a high forecast of $94.00 and a low forecast of $58.00.
: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last year. There are currently 7 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CVS shares.
: According to analysts, CVS Health's stock has a predicted upside of 27.18% based on their 12-month stock forecasts.
: Over the previous 90 days, CVS Health's stock had 3 upgrades by analysts.
: CVS Health has been rated by research analysts at Barclays, Cantor Fitzgerald, Evercore ISI, Mizuho, Royal Bank of Canada, TD Cowen, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like CVS Health more than other "retail/wholesale" companies. The consensus rating score for CVS Health is 2.65 while the average consensus rating score for "retail/wholesale" companies is 2.51. Learn more on how CVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

This page (NYSE:CVS) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CVS Health (CVS) Stock Forecast & Price Target